JP2012046498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012046498A5 JP2012046498A5 JP2011160922A JP2011160922A JP2012046498A5 JP 2012046498 A5 JP2012046498 A5 JP 2012046498A5 JP 2011160922 A JP2011160922 A JP 2011160922A JP 2011160922 A JP2011160922 A JP 2011160922A JP 2012046498 A5 JP2012046498 A5 JP 2012046498A5
- Authority
- JP
- Japan
- Prior art keywords
- examples
- purified water
- comparative example
- unpleasant taste
- comparative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000052 comparative effect Effects 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 6
- 229960002373 loxoprofen Drugs 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 235000002906 tartaric acid Nutrition 0.000 description 5
- 239000011975 tartaric acid Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- -1 Furthermore Chemical compound 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011160922A JP5853462B2 (ja) | 2010-07-30 | 2011-07-22 | 内服液剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010171851 | 2010-07-30 | ||
| JP2010171851 | 2010-07-30 | ||
| JP2011160922A JP5853462B2 (ja) | 2010-07-30 | 2011-07-22 | 内服液剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012046498A JP2012046498A (ja) | 2012-03-08 |
| JP2012046498A5 true JP2012046498A5 (cg-RX-API-DMAC10.html) | 2014-08-21 |
| JP5853462B2 JP5853462B2 (ja) | 2016-02-09 |
Family
ID=45901791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011160922A Active JP5853462B2 (ja) | 2010-07-30 | 2011-07-22 | 内服液剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5853462B2 (cg-RX-API-DMAC10.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61268621A (ja) * | 1985-05-21 | 1986-11-28 | Sankyo Co Ltd | シロツプ製剤 |
| JPH10273435A (ja) * | 1997-01-29 | 1998-10-13 | Fujisawa Pharmaceut Co Ltd | 内服用液剤 |
| JP2001010977A (ja) * | 1999-06-29 | 2001-01-16 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
| JP2001031562A (ja) * | 1999-07-16 | 2001-02-06 | Taisho Pharmaceut Co Ltd | 内服液剤 |
-
2011
- 2011-07-22 JP JP2011160922A patent/JP5853462B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| AR060932A1 (es) | Producto y su uso y elaboracion | |
| EA201490876A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| PH12016501974A1 (en) | Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides | |
| JP2016516442A5 (cg-RX-API-DMAC10.html) | ||
| WO2008073764A3 (en) | Substantially pure fluorescein | |
| JP2015528515A5 (cg-RX-API-DMAC10.html) | ||
| WO2012068998A3 (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
| RU2020119597A (ru) | Композиция для лечения пациента с респираторным заболеванием, обусловленным хроническим воспалением, способ получения и применение указанной композиции | |
| MA30200B1 (fr) | Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique | |
| TW200616536A (en) | Animal for drug efficacy evaluation, method for developing chronic obstructive pulmonary disease in animal for drug efficacy evaluation, and method for evaluation drug efficacy using the animal | |
| JP2012046493A5 (cg-RX-API-DMAC10.html) | ||
| MY175936A (en) | A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vegina syndrome or colpoxerosis disease in an mammal | |
| Pumin | Design Makes a Splash | |
| Pan et al. | Peer-And Sibling-assisted Aquatic Program For Children With Autism Spectrum Disorders: 3096Board# 59 June 4 8: 00 AM-9: 30 AM | |
| JP2012046496A5 (cg-RX-API-DMAC10.html) | ||
| Hew et al. | A36 CLINICAL PROBLEMS IN ASTHMA AND ALLERGY: Clinical Effectiveness Of Omalizumab In Severe Allergic Asthma Above The Recommended Dosing Range: The Australian Xolair Registry | |
| RU2005114330A (ru) | Способ моделирования варикоцеле | |
| Lowry | Bleeding complications in paediatric patients: 3 case reports | |
| Reid | Emerging Epidemics | |
| Al-Dorzi et al. | The Impact of Mean Arterial, Intra-Abdominal and Abdominal Perfusion Pressures on the Mortality of Critically Ill Cirrhotic Patients. | |
| RUILI | The Pledge to Reform | |
| Marti | Methylphenidate/alcohol interaction | |
| De Vuono | Acute gout arthropathy following switch to generic version: case report | |
| UA29235U (ru) | Способ повышения производительности и стресcоустойчивости поросят |